InMed provides 2026 pipeline outlook; pre-IND meetings targeted for INM-901 and INM-089

InMed Pharmaceuticals Inc.

Preclinical data for INM-901 shows reduced neuroinflammatory biomarkers, neuroprotection, and behavioral improvements in Alzheimer's models.
Targeting pre-IND meeting with FDA for INM-901 in Q3 2026 and for INM-089 in Q4 2026.
INM-901 aims for IND submission and Phase 1 clinical trial initiation in 2027.
INM-089 (dry AMD) completed dose-ranging studies; drug substance process in place for IND-enabling studies.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.